In this episode, Karim Fizazi, MD, PhD, and Joaquin Mateo, MD, PhD, consider the potential implications of ongoing and planned clinical trials using PARP inhibitors in combination with other therapies to treat men with prostate cancer including:PARP inhibitors combined with androgen receptorsPhase III trials of PARP inhibitors with androgen receptor–directed therapyPARP inhibitors combined with immunotherapyPARP inhibitors and DNA damaging agentsPresenters:Karim Fizazi, MD, PhDFull ProfessorCancer MedicineInstitut Gustave RousseyVillejuif, FranceJoaquin Mateo, MD, PhDAttending PhysicianMedical OncologyVall d’Hebron University Hospital,Barcelona, SpainContent is part of an online program supported by an educational grant from Pfizer Inc.Link to full program, including associated downloadable Podcast Pearls slidesets, expert analysis, and expert commentary:https://bit.ly/3spLzqa

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related